Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free FBT Stock Alerts

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation logo
GBX 1,880.80 +40.60 (+2.21%)
As of 05/5/2026 11:58 AM Eastern
Compare

FBT vs. SOPH, PRSM, KAPE, KNOS, and TRST

Should you be buying First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? The main competitors of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Sophos Group plc (SOPH.L) (SOPH), Blue Prism Group (PRSM), Kape Technologies (KAPE), Kainos Group (KNOS), and Trustpilot Group (TRST). These companies are all part of the "software - application" industry.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Sophos Group plc (SOPH.L)?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Sophos Group plc (SOPH.L) (LON:SOPH) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Sophos Group plc (SOPH.L) N/A N/A N/A

In the previous week, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 equaled Sophos Group plc (SOPH.L)'saverage media sentiment score.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Sophos Group plc (SOPH.L) Neutral

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Sophos Group plc (SOPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Sophos Group plc (SOPH.L)£726.90M0.00N/A£1.70N/A

Summary

Sophos Group plc (SOPH.L) beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 3 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Blue Prism Group?

Blue Prism Group (LON:PRSM) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Blue Prism GroupN/A N/A N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

In the previous week, Blue Prism Group's average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Blue Prism Group Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Blue Prism Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blue Prism Group£167.30M0.00N/A-£53.80N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

Summary

Blue Prism Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 2 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kape Technologies?

Kape Technologies (LON:KAPE) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Kape Technologies has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kape Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kape Technologies£623.48M0.00£70.92M£0.15N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

11.4% of Kape Technologies shares are owned by institutional investors. 81.1% of Kape Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kape Technologies has a net margin of 11.37% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kape Technologies' return on equity of 6.97% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kape Technologies11.37% 6.97% 3.47%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

In the previous week, Kape Technologies' average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Kape Technologies Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Summary

Kape Technologies beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 8 of the 8 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kainos Group?

Kainos Group (LON:KNOS) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kainos Group£380.27M2.53£48.81M£24.8033.13
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

40.7% of Kainos Group shares are held by institutional investors. 19.8% of Kainos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kainos Group has a net margin of 8.08% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kainos Group's return on equity of 25.32% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kainos Group8.08% 25.32% 14.45%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Kainos Group presently has a consensus price target of GBX 1,163.40, suggesting a potential upside of 41.62%. Given Kainos Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kainos Group
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Kainos Group had 2 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 2 mentions for Kainos Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Kainos Group's average media sentiment score of 0.59 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Kainos Group is being referred to more favorably in the media.

Company Overall Sentiment
Kainos Group Positive
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Summary

Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 13 of the 13 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Trustpilot Group?

Trustpilot Group (LON:TRST) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Trustpilot Group has a net margin of 2.97% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Trustpilot Group's return on equity of 64.11% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Trustpilot Group2.97% 64.11% 1.45%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Trustpilot Group presently has a consensus price target of GBX 321, suggesting a potential upside of 19.98%. Given Trustpilot Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Trustpilot Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trustpilot Group
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

37.8% of Trustpilot Group shares are held by institutional investors. 18.6% of Trustpilot Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Trustpilot Group had 4 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 4 mentions for Trustpilot Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Trustpilot Group's average media sentiment score of 0.88 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Trustpilot Group is being referred to more favorably in the media.

Company Overall Sentiment
Trustpilot Group Positive
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Trustpilot Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Trustpilot Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trustpilot Group£261.05M3.96£20.08M£1.80148.64
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

Summary

Trustpilot Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 13 of the 13 factors compared between the two stocks.

Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBT vs. The Competition

Export
MetricFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationSoftware IndustryComputer SectorLON Exchange
Market Cap£771.53M£5.31B£37.08B£2.73B
Dividend YieldN/A3.96%3.19%6.11%
P/E Ratio-1,709.8227.33163.90365.30
Price / SalesN/A257.17619.5287,989.37
Price / Cash3.5417.1445.7427.89
Price / BookN/A4.299.297.39
Net IncomeN/A£22.26M£1.03B£5.89B
7 Day Performance2.16%2.19%5.19%1.16%
1 Month Performance0.77%8.49%13.75%5.27%
1 Year Performance24.29%-2.14%169.69%80.16%

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBT
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
N/AGBX 1,880.80
+2.2%		N/A+24.8%£771.53MN/AN/A20
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
PRSM
Blue Prism Group
N/AN/AN/AN/A£1.24B£167.30MN/A1,025
KAPE
Kape Technologies
N/AN/AN/AN/A£1.22B£623.48M1,900.00850
KNOS
Kainos Group
3.8055 of 5 stars		GBX 839
-0.5%		GBX 1,163.40
+38.7%		+8.7%£981.40M£380.27M33.832,953

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FBT) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel